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Psoriasis, a Disorder Associated with a Thl-Type T-Cell Immune Response 
There is mounting evidence that psoriasis, which is associated with 
a human leukocyte antigen B27+ arthritis in 5% of patients, may be 
an immunologically mediated disorder. In addition to hyperproli-
feration of keratinocytes, it is characterized by infiltration with 
T lymphocytes and neutrophils, and there is some evidence that 
infiltrating T lymphocytes may play an important role in its pa~ho­
genesis. For example, It has been shown that the T -cell- denved 
lymphokines interferon (IFN-Y) and interleukin 2 (IL-2) mayexa-
cerbate psoriasis, and some patients benefit from treatment with 
cyclosporine A, known to suppress both proliferation and cytokine 
production by T cells, or with anti-CD4 antibodies, which suppress 
immune reactions mediated by CD4-positive T-helper lympho-
cytes. It has been demonstrated that epidermal T cells produce the 
disease-promoting cytokine IFN-y, but mediators that may 
downregulate the production and effects ofIFN-y, such as IL-4 and 
IL-IO, have not been studied. In this issue, Schlaak et al (p. 145) 
present data showing that T lymphocytes from epidermal psoriatic 
lesions and psoriatic arthritis produce IFN-y both ill vivo and in vitro 
but little or no IL-4 and IL-IO. In recent years it has been widely 
accepted that mediators produced by T-helper lymphocytes play an 
important role in the regulation of immune reactions. T cells that 
produce IFN-y but not IL-4 or IL-l 0 are thought to facilitate cellu-
lar immune reactions such as delayed-type hypersensitivity and to 
suppress humoral reactions and are classified as Th 1 cells. T cells 
that produce IL-4 and IL-I0 and in contrast suppress cellular im-
mune reactions but facilitate humoral, especially allergic, immune 
reactions are classified as Th2 cells. It has been suggested that the 
two subsets ofT cells have the capacity to antagonize each other and 
thereby control detrimental overreactions of the immune system 
and that because only IFN-y, but not IL-4 or IL-I0, are detectable in 
psoriasis, the disease may be associated with an impaired capacity to 
maintain immunologic homeostasis. If these findings are indeed 
involved in the pathogenesis of psoriasis, it may be possible to treat 
the disease by modulating critical cytokines. For example, IL-IO, 
which can downregulate IFN-y production, may be useful, and 
mediators that block the induction of Th l-like immune responses 
may also have therapeutic potential. 
Keratinocytes Stimulate T Cells in the Presence of Superantigens 
Unlike conventional antigens, superantigens, 20-40 kD proteins 
produced by various microorganisms including staphylococci, 
crosslink major histocompatibility complex (MHC) class II mole-
cules on antigen-presenting cells with the T-cell receptor (TCR) P 
chain ofT cells expressing certain P chains. The result of this cross-
linking is activation of the T cells, leading to proliferation of the T 
cells and release of cytokines. Classical protein antigens ("nominal 
antigens") are processed by antigen-presenting cells to immuno-
genic fragments, which are then recognized by the variable regions 
of the TCR ex and P chains. This processing results in recognition 
exclusively by antigen-specific T-cell clones. In contrast, superanti-
gens bind to a constant region of the TCR P chains, thus producing 
polyclonal, antigen non-specific T-cell activation. During inflam-
mation, keratinocytes are induced to express MHC class II mole-
cules, but the function of these MHC class II molecules is obscure, 
because keratinocytes are incapable of processing antigens. In this 
issue, Strange et al (p. 150) tested the hypothesis that because super-
antigens are not processed, keratinocytes may present superantigens 
to T cells, an event that could activate the T cells. The authors 
induced MHC class II molecules on keratinocytes with gamma-in-
terferon and demonstrated that these MHC class 11+ keratinocytes 
induced proliferation of T cells in the presence of superantigens. 
Studies of concentration dependence showed that concentrations of 
superantigen as low as 0.1 ng per ml induced proliferation ofT cells, 
and time-course studies showed that the T-cell proliferation peaked 
early, at day 3. The authors further demonstrated that this T-cell 
stimulation is dependent upon physical contact between keratino-
cytes and T cells and is not caused by cytokines released from the 
keratinocytes. Finally, inhibition studies with antibodies to MHC 
class I and II molecules and to ICAM-I were consistent with the 
0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 
139 
140 IN THIS ISSUE 
proposed mechanism of direct binding to MHC cl~ss II molecu~es. 
These findings suggest that MHC class n+ keratmocytes, which 
may inhibit inflammation arising from presentation of nominal 
antigens, may up-regulate inflammation when superantigens are 
present. T -cel~ activation and subseq~ent rel~ase of ~yto~ines may 
be important m epidermal hyperplasia assoClated with mflamma-
tory skin diseases inasmuch as it was recently demonstrated that 
lesional psoriatic T-cell clones release growth factors that induce 
keratinocyte proliferation (] Invest Dermatoll0l:690-694, 1993). 
Lesional skin of several inffammatory skin diseases, e.g., psoriasis, 
atopic dermatitis, and contact dermatitis, is characterized by epider-
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mal hyperplasia, the presence of MHC class II+ keratinocytes, and 
colonization by staphylococci capable of producing superantigen. 
These findings taken together suggest that superantigens released 
from staphylococci may enter the skin, bind to MHC class II mole-
cules on Langerhans cells or keratinocytes, and then crosslink these 
MHC class II molecules to receptors on T cells, thereby activating T 
cells present in skin. These activated T cells may then release factors 
that stimulate keratinocyte growth. Thus superantigens released 
from staphylococci may participate in sustaining both the inflam-
mation and the hyperplasia of skin lesions. 
Molecular Heterogeneity of Severe Dystrophic Epidermolysis Bullosa 
Severe dystrophic epidermolysis bullosa (EBD) presents with a clin-
ically rather uniform phenotype of severe blistering and scarring, 
and digits become fused with advancing age, a phenomenon called 
mutilation. The skin of most affected individuals lacks ultrastruc-
turally distinct anchoring fibrils, and collagen VII, the main com-
ponent of the fibrils, is absent or drastically reduced. These observa-
tions as well as linkage studies suggested that mutations in the gene 
for collagen VII (COL7Al) may be involved in this EBD subtype, 
and subsequently mutations, e.g., premature stop codons in the 5' 
end of the gene, were identified in some families with mutilating 
EBD (Hilal et al: ] Invest Dermato! 100:499, 1993). In this issue, 
Kalinke et al (p. 260) report on heterogeneity of the mutations 
leading to severe dystrophic EB. In a collection of European patients 
defined by apparent lack of collagen VII protein in the skin and in 
cutaneous cells in vitro, collagen VII mRNA of correct size was 
isolated from fibroblasts of all probands, and none of these patients 
were found by PCR-SSCP analysis to have a mutation in the 5' end 
of the COL7Al gene that codes for the N -terminal globular do-
main of collagen VII, as had been described earlier. Also in this issue, 
Konig et al (p. 155) describe another patient with the same severe 
phenotype but with the unusual finding of abundant normal an-
choring fibrils and overexpression of collagen VII in skin as well as 
in keratinoeytes ill vitro. The patient's keratinocytes produced two-
to three-fold increased amounts of collagen VII mRNA and protein 
irl vitro, and the matrix metalloproteinase activities in fibroblasts 
were normal, suggesting that neither gross strucrural defects of 
collagen VII nor its excessive degradation caused blistering in this 
individual. The reason for the overexpression is not known but in 
analogy with other hereditary connective tissue disorders it could 
reflect a dysregulated feedback mechanism. These results suggest 
that the molecular mechanisms underlying the severe dystrophic 
mutilating EBD may be heterogeneous and that the type of dis-
turbed cohesion of the dermo-epidermal junction that appears to be 
caused by mutations in the COL7Al gene may in some cases be 
caused by genetic defects in other basement membrane components. 
The dermo-epidermal junction consist~ of an integral network of 
structural macromolecules and depends strongly on their interac-
tions for its architecture and its function. The findings raise the 
possibility that a structural defect of components other than type 
VII collagen may lead to the EBD phenotype. 
FK506 Stimulates Growth of Hair 
FK506, a T -cell- specific immunosuppressantlike cyclosporin A, is 
effective against graft rejection at much lower doses than is CsA. 
Both compounds inhibit T-cell activation by interfering with the 
production o~ IL-2 .by inhibiting 1~-2 gene expression, probably 
through the lllhlblt10n of calcmeunn, a Ca++ I calmodulin-depen-
dent phosphatase. Clinical studies indicate that FK506 induces 
common side effects similar to those associated with CsA. One of 
the most common side effects of CsA is hypertrichosis, which is 
observed not only in normal but also in pathologic conditions of 
hair gro~th, e.g., in patients with alopecia areata and in some pa-
tients With male-pattern alopeCia. Although hypertrichosis is in-
duced by both topical and oral administration of CsA, administra-
tion of FK506 has not been associated with hypertrichosis . 
Recently Jiang, Yamamoto, and Kato demonstrated that topically 
applied FK506 markedly inhibits tumor promotion caused by 12-
O-tetradecanoylphorbol-13-acetate (TPA) in two-stage carcino-
genesis in mouse skin (Carcinogenesis 14:67 - 71, 1993). During 
these experiments, they also observed that topically applied FK506 
appeared to stimulate growth of hair. In this issue, Yamamoto et al 
(p . 160) studied the hair-growth - stimulating effect of FK506 and 
found that the topical application of FK506 to skin of mice, rats, Or 
hamsters stimulated hair growth in dose-dependent fashion. This 
effect was observed only when FK506 was applied topically, not 
with oral administration, even in doses associated with marked im-
munosuppression. Treatment of mice for up to 6 months with topi-
cal FK506 did not affect the health of the mice, further supporting 
the idea that the ability of FK506 to stimulate hair growth does not 
result from its immunosuppressive effect. In further support of this 
idea, Yamamoto et al found that FK506 directly stimulates growth 
of hair follicles in vitro. Although it has yet to be determined 
whether FK506 stimulates hair growth in humans, this possibility 
needs to be studied. 
